双黄连雾化吸入应用于喘憋型肺炎治疗的临床研究  

Clinical Study of Shuanghuanglian Inhalation in Asthmatic Pneumonia Treatment

作　　者：陈培锋 陈金寅 

机构地区：[1]诸暨市人民医院呼吸内科,浙江诸暨311800

出　　处：《中华中医药学刊》2014年第9期2294-2296,共3页Chinese Archives of Traditional Chinese Medicine

摘　　要：目的：探讨双黄连雾化吸入应用于喘憋型肺炎治疗的疗效。方法：2010年6月—2012年6月收治的喘憋型肺炎患者90例,按随机数字表法分为观察组和对照组,每组45例。对照组患者给予病毒唑10~15 mg/kg＋注射用α-糜蛋白酶2.5 mg＋地塞米松0.3 mg/kg＋生理盐水20 mL,雾化吸入,2次/d,疗程5 d。观察组患者给予双黄连冻干粉0.2 g＋生理盐水5 mL,雾化吸入,3次/d。比较两组发热、咳嗽、肺部罗音及喘憋消失时间,并评价疗效。结果：观察组总有效率为94.29%（33/35）,对照组为71.43%（25/35）,差异有统计学意义（χ2=5.68,P〈0.05）。观察组治疗后咳嗽、发热、咳痰、喘息、肺部体征评分均显著低于对照组,差异有统计学意义（t=5.34、4.78、4.56、4.92、4.31,P〈0.05）。观察组发热、咳嗽、肺部罗音及喘憋消失时间均明显短于对照组,差异有统计学意义（P〈0.05）。观察组患者住院时间平均为（7.5±1.7）d,对照组为（11.3±2.4）d,差异有统计学意义（t=4.82,P〈0.05）。结论：双黄连雾化吸入治疗喘憋型肺炎作用迅速,较快解决患者痛苦,显著提高疗效,缓解症状和体征,不良反应少,易于操作,不失为治疗喘憋型肺炎的理想药物。Objective ： To investigate the effect of Shuanghuanglian inhalation in asthmatic pneumonia treatment. Meth- ods ： From June 2010 to June 2012 in our hospital,90 cases with wheezing pneumonia were randomly divided into observa- tion group and control group, 45 cases in each group. The control group was treated with ribavirin injection 10 - 15 mg ＋ with α - chymotrypsin 2.5 mg ＋ dexamethasone O. 3 mg＋ saline inhalation, 20 mL, 2/d, for 5d. The observation group was treated with Shuanghuanglian Lyophilized Powder 0.2 g ＋ saline inhalation 5mL, 3/d. We compared two groups fe- ver, cough, tung rale and wheezing disappearance time and evaluated the effect. Results ： The total effective rate of obser- vation group was 94.29% （33/35） and the control group＇s was 71.43% （25/35）. The difference was statistically sig- nificant （ X2 = 5.68, P 〈 0.05 ）. After treatment,the observation group＇ s cough, fever, cough, wheezing and pulmonary symptoms scores were significantly lower than those in the control group and the difference was statistically significant （t = 5.34, 4.78, 4.56, 4.92, 4.31, P 〈 0.05）. The observation groupg fever, cough, lung rale and wheezing disappearance time were significantly shorter than those of the control group and the difference was statistically significant （P 〈 0.05 ）. The observation groupg average hospital time was （7.5 ± 1.7） d and the control group g was （11.3 ± 2.4） d. The difference was statistically significant （ t = 4.82, P 〈 0. 05 ）. Conclusion ： Shuanghuanglian inhalation in treating asthmatic pneumonia can quickly solve the suffering of patients and improve the curative effect, symptoms and signs, adverse reactions. It is easy to operate and it is an ideal drug treatment of asthma hold type of pneumonia.

关 键 词：双黄连 雾化吸入 喘憋型肺炎 

分 类 号：R563.1[医药卫生—呼吸系统]